||Size (96 tests)
||Size (480 tests)
||Biotinylated anti-CTLA-4 antibody
How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development.
CTLA-4 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of ipilimumab. Many investigational anti-CTLA-4 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
The enclosed ELISA assay kit for anti-CTLA-4 h-mAb in human serum is based on an enzyme immunoassay (ELISA) between recombinant CTLA-4 protein (ECD) and a biotinylated anti-CTLA-4 monoclonal antibody. The method employs the principle of competitive ELISA, allowing quantification of monoclonal anti-CTLA-4 antibodies in human serum.
The assay only involves the following steps:
- Coat the plate with human CTLA-4;
- Add the mixture of your sample and biotinylated anti-CTLA-4 antibody;
- Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate;
- Record the OD readings and analyze the serum concentration.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Wide Coverage - There is no requirement for the species and subtype of the antibody.
Easy Process - There is no longer a need to generate anti-drug antibodies for PK studies.
Clean Result - The use of the biotinylated antibody in the competitive ELISA significantly alleviates the issue of background noise issue that often occurs in traditional ELISA method.
Upon receipt, please store all items at -20 ℃. After reconstitution, the stock solution should be kept at -80 ℃. It is recommend not to freeze thaw more than 3 times. No activity loss is observed after storage at:
- Room temperature (RT) for 1 month in lyophilized state;
- -20 ℃ for 6 months in lyophilized state;
- -80 ℃ for 4 months under sterile conditions after reconstitution.
Inhibition of CTLA-4: biotinylated anti-CTLA-4 antibody binding by an anti-CTLA-4 antibody.
Serial dilutions of the Therapeutic Anti-CTLA-4 Antibody (1:2 serial dilutions, from 20 μg/mL to 0.039 μg/mL) was added into CTLA-4: Biotinylated Anti-CTLA-4 Antibody binding reactions.